Clinical Trial Update: Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

View source ↗

Summary

A study led by Tempus AI is evaluating minimal residual disease in breast cancer by longitudinal ctDNA profiling to track disease status across several subtypes…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer
• Triple-negative Breast Cancer

Snippet

Sponsor: Tempus AI | Conditions: Breast Cancer, TNBC - Triple-Negative Breast Cancer | Status: RECRUITING